12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Company News  |  Deals

Cato Research Ltd., VistaGen deal

VistaGen partnered with CRO Cato Research and its Cato Ventures venture capital affiliate to indentify and develop small molecule drugs candidates that were discontinued in preclinical development...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >